Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
84 hedge funds and large institutions have $719M invested in Adverum Biotechnologies in 2014 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 29 increasing their positions, 14 reducing their positions, and 7 closing their positions.
386% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 7
107% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 14
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
72% more capital invested
Capital invested by funds: $419M → $719M (+$300M)
45% more funds holding
Funds holding: 58 → 84 (+26)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$11M |
| 2 |
JP Morgan Chase
New York
|
+$10.7M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$4.74M |
| 4 |
Millennium Management
New York
|
+$4.4M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$3.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$16.7M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.15M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$1.55M |
| 4 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
-$998K |
| 5 |
UBS AM
Chicago,
Illinois
|
-$985K |
ADVM Hedge Fund Activity: Q4 2014 in Review
84 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q4 2014, worth a combined $719M — up 72% from $419M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ADVM positions and 7 closed out — a net gain of 27 holders — while 29 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $11M. The largest seller was Deerfield Management, cutting an estimated $16.7M.
- 84 institutional investors held Adverum Biotechnologies (ADVM) as of Q4 2014, up from 58 in Q3 2014.
- Funds reported $719M of Adverum Biotechnologies stock for Q4 2014, up 72% quarter-over-quarter.
- 34 funds opened new Adverum Biotechnologies positions in Q4 2014 and 7 closed out, a net change of +27 holders.
- The largest Adverum Biotechnologies buyer in Q4 2014 was BlackRock Fund Advisors, an estimated $11M added.
- The largest Adverum Biotechnologies seller in Q4 2014 was Deerfield Management, an estimated $16.7M sold.
Based on aggregated 13F filings for Q4 2014.